Femme et Homme
- | Pays :
- United States
- Estonia
- Germany
- ...
- | Organes : -
- | Spécialités : -
Extrait
A multi-center, randomized, open-label, parallel-group, repeat dose study in asthma patients with elevated eosinophils. Eligible subjects will receive 3 doses (28 days apart) of mepolizumab given intravenous (IV) or subcutaneously (SC). Blood samples for safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity analysis, as well as safety/tolerability assessments will be collected throughout the study
Critère d'inclusion
- Asthma